Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDNurix Therapeutics, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 2 | -$0.97 | -$0.67 | -$0.78 |
| Q2 2024 | 2 | -$0.80 | -$0.55 | -$0.63 |
| Q3 2024 | 4 | -$0.86 | -$0.60 | -$0.69 |
| Q4 2024 | 10 | -$0.90 | -$0.52 | -$0.68 |
| Q1 2025 | 5 | -$0.72 | -$0.66 | -$0.68 |
| Q2 2025 | 2 | -$0.87 | -$0.60 | -$0.69 |
| Q3 2025 | 2 | -$0.90 | -$0.63 | -$0.72 |
| Q4 2025 | 2 | -$0.91 | -$0.63 | -$0.73 |
| Q1 2026 | 2 | -$0.98 | -$0.68 | -$0.78 |
| Q2 2026 | 1 | -$1.04 | -$0.72 | -$0.83 |
| Q3 2026 | 1 | -$1.29 | -$0.90 | -$1.03 |
| Q4 2026 | 1 | -$1.22 | -$0.84 | -$0.97 |
Nurix Therapeutics, Inc. Earnings Date And Information
Nurix Therapeutics, Inc. last posted its earnings results on Friday, October 11th, 2024. The company reported $-0.67 earnings per share for the quarter, missing analysts' consensus estimates of $-0.67 by $0. The company had revenue of 12.59 M for the quarter and had revenue of 76.99 M for the year. Nurix Therapeutics, Inc. has generated $-3 earnings per share over the last year ($-2.65 diluted earnings per share) and currently has a price-to-earnings ratio of -8.05. Nurix Therapeutics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, February 13th, 2025 based on prior year's report dates.
Nurix Therapeutics, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 10/11/2024 | Q3 2024 | -$0.67 | -$0.67 | 0 | $14.97 M | $12.59 M |
| 07/11/2024 | Q2 2024 | -$0.66 | -$0.71 | -0.05 | $22.11 M | $12.09 M |
| 04/10/2024 | Q1 2024 | -$0.80 | -$0.76 | 0.04 | $16.59 M | |
| 02/15/2024 | Q4 2023 | -$0.51 | -$0.77 | -0.26 | $15.16 M | |
| 10/12/2023 | Q3 2023 | -$0.69 | -$0.68 | 0.01 | $11.94 M | $18.47 M |
| 07/13/2023 | Q2 2023 | -$0.63 | -$0.40 | 0.23 | $26.24 M | $30.68 M |
| 04/13/2023 | Q1 2023 | -$0.90 | -$0.65 | 0.25 | $12.69 M | |
| 02/09/2023 | Q4 2022 | -$0.68 | -$0.77 | -0.09 | $6.78 M | |
| 10/06/2022 | Q3 2022 | -$0.99 | -$0.88 | 0.11 | $12.07 M | $10.79 M |
| 07/07/2022 | Q2 2022 | -$1.00 | -$1.00 | 0 | $10.51 M | $11.43 M |
| 04/08/2022 | Q1 2022 | -$0.95 | $9.62 M | |||
| 01/28/2022 | Q4 2021 | -$0.85 | $7.40 M | |||
| 10/14/2021 | Q3 2021 | -$0.63 | -$0.65 | -0.02 | $8.54 M | $10.25 M |
| 07/13/2021 | Q2 2021 | -$0.54 | -$0.60 | -0.06 | $8.23 M | $7.09 M |
| 04/13/2021 | Q1 2021 | -$0.46 | -$0.63 | -0.17 | $5.01 M | |
| 02/16/2021 | Q4 2020 | -$0.54 | -$0.51 | 0.03 | $6.69 M | |
| 10/14/2020 | Q3 2020 | -$0.41 | -$1.09 | -0.68 | $6.35 M | $4.09 M |
| 05/30/2020 | Q2 2020 | $0.22 | $4.18 M | |||
| 02/28/2020 | Q1 2020 | -$0.60 | $2.86 M | |||
| 11/29/2019 | Q4 2019 | -$0.65 | $1.86 M |
Nurix Therapeutics, Inc. Earnings: FAQ's
When is Nurix Therapeutics, Inc.'s earnings date?
Nurix Therapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, February 13th, 2025 based off last year's report dates.
How can I listen to Nurix Therapeutics, Inc.'s earnings conference
call?
The conference call for Nurix Therapeutics, Inc.'s latest earnings report can be listened to online.
How can I read Nurix Therapeutics, Inc.'s conference call transcript?
The conference call transcript for Nurix Therapeutics, Inc.'s latest earnings report can be read online.
How much revenue does Nurix Therapeutics, Inc. generate each year?
Nurix Therapeutics, Inc. (:NRIX) has a recorded annual revenue of $76.99 M.
How much profit does Nurix Therapeutics, Inc. generate each year?
Nurix Therapeutics, Inc. (:NRIX) has a recorded net income of $76.99 M. Nurix Therapeutics, Inc. has generated $-2.65 earnings per share over the last four quarters.
What is Nurix Therapeutics, Inc.'s price-to-earnings ratio?
Nurix Therapeutics, Inc. (:NRIX) has a price-to-earnings ratio of -8.05 and price/earnings-to-growth ratio is -23.5.